Evidence map›Paper›PMID 26807226›Full record

ArticleMolecular and clinical oncology2015

Enhanced antitumor effect of combining chemotherapy with Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes in mice with EBV-related non-Hodgkin's lymphoma.

Rui Deng, Hai Yi, Yi-Lan Liu, Fang-Yi Fan, L I Fu, Ye-Cheng Li, Guo-Shun Li, Si-Han Lai, Xiao-Juan Miao, Yan-Rong Shuai and 6 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Rui DengDepartment of Hematology, Hematopoietic Stem Cell Transplantation and Cell Immunotherapy Center, Cheng Du Military General Hospital of PLA, Chengdu, Sichuan 610083, P.R. China.
Hai YiDepartment of Hematology, Hematopoietic Stem Cell Transplantation and Cell Immunotherapy Center, Cheng Du Military General Hospital of PLA, Chengdu, Sichuan 610083, P.R. China.
Yi-Lan LiuDepartment of Hematology, Hematopoietic Stem Cell Transplantation and Cell Immunotherapy Center, Cheng Du Military General Hospital of PLA, Chengdu, Sichuan 610083, P.R. China.
Fang-Yi FanDepartment of Hematology, Hematopoietic Stem Cell Transplantation and Cell Immunotherapy Center, Cheng Du Military General Hospital of PLA, Chengdu, Sichuan 610083, P.R. China.
L I FuDepartment of Hematology, Hematopoietic Stem Cell Transplantation and Cell Immunotherapy Center, Cheng Du Military General Hospital of PLA, Chengdu, Sichuan 610083, P.R. China.
Ye-Cheng LiDepartment of Hematology, Hematopoietic Stem Cell Transplantation and Cell Immunotherapy Center, Cheng Du Military General Hospital of PLA, Chengdu, Sichuan 610083, P.R. China.
Guo-Shun LiDepartment of Translational Medicine, Experimental Medical Research Center, Cheng Du Military General Hospital of PLA, Chengdu, Sichuan 610083, P.R. China.
Si-Han LaiDepartment of Hematology, Hematopoietic Stem Cell Transplantation and Cell Immunotherapy Center, Cheng Du Military General Hospital of PLA, Chengdu, Sichuan 610083, P.R. China.
Xiao-Juan MiaoDepartment of Hematology, Hematopoietic Stem Cell Transplantation and Cell Immunotherapy Center, Cheng Du Military General Hospital of PLA, Chengdu, Sichuan 610083, P.R. China.
Yan-Rong ShuaiDepartment of Hematology, Hematopoietic Stem Cell Transplantation and Cell Immunotherapy Center, Cheng Du Military General Hospital of PLA, Chengdu, Sichuan 610083, P.R. China.
Guang-Cui HeDepartment of Hematology, Hematopoietic Stem Cell Transplantation and Cell Immunotherapy Center, Cheng Du Military General Hospital of PLA, Chengdu, Sichuan 610083, P.R. China.
Y I WangDepartment of Hematology, Hematopoietic Stem Cell Transplantation and Cell Immunotherapy Center, Cheng Du Military General Hospital of PLA, Chengdu, Sichuan 610083, P.R. China.
Yan ZengDepartment of Hematology, Hematopoietic Stem Cell Transplantation and Cell Immunotherapy Center, Cheng Du Military General Hospital of PLA, Chengdu, Sichuan 610083, P.R. China.
Hao-Ping SunDepartment of Hematology, Hematopoietic Stem Cell Transplantation and Cell Immunotherapy Center, Cheng Du Military General Hospital of PLA, Chengdu, Sichuan 610083, P.R. China.
Ling QiuDepartment of Hematology, Hematopoietic Stem Cell Transplantation and Cell Immunotherapy Center, Cheng Du Military General Hospital of PLA, Chengdu, Sichuan 610083, P.R. China.
Y I SuDepartment of Hematology, Hematopoietic Stem Cell Transplantation and Cell Immunotherapy Center, Cheng Du Military General Hospital of PLA, Chengdu, Sichuan 610083, P.R. China.
Chengdu Military General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epstein-Barr virus (EBV)-related non-Hodgkin's lymphoma (NHL) represents a major problem in hematological clinical studies due to its drug tolerance and refractoriness. EBV infection is a key factor driving the process of tumor growth. Immune therapy is an important biotherapeutic method of treating cancer, which is attracting increasing attention. We hypothesized that combining conventional chemotherapy with immune therapy in the treatment of EBV-related NHL may achieve better outcomes. First, we successfully cloned large numbers of EBV-specific T cells by immune stimulation

Indexed as

chemotherapycytotoxic T cellEpstein-Barr virusimmunotherapylymphoma

Identifiers

PMID26807226
PMCPMC4665265
OpenAlexW2165865316

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.